StockNews.AI
RPID
StockNews.AI
180 days

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025

1. RPID to release Q4 and FY 2024 financials on Feb 28, 2025. Earnings details remain forthcoming. 2. Management to host a live webcast at 8 AM ET. Investors can access and replay the call. 3. The company highlights its innovative automation in microbial quality control. This underpins faster, accurate healthcare production. 4. Global operations in the US and Europe support RPID's market presence. The tech focus may influence investor sentiment.

Earnings
-12.3%Current Return
VS
-1.72%S&P 500
$3.6602/20 04:35 PM EDTEvent Start
$3.2102/21 10:46 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The announcement is a standard earnings release schedule. Historically, such scheduled events produce limited price movement until actual earnings are revealed.

How important is it?

While earnings releases are crucial catalysts, this announcement adds no new strategic developments. The impact will depend on the forthcoming financial results.

Why Short Term?

Earnings announcements typically create immediate market volatility. Previous releases have shown short-term responses based on results.

Related Companies

TMO
LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2024 financial results prior to the market open on Friday, February 28, 2025. In conjunction with the release, the Company’s management team will host a webcast conference call at 8:00 a.m. ET on Friday, February 28, 2025. The live audio webcast will be accessible on the Company’s website and can be accessed with this link. The webcast will be archived and available for replay after the event. About Rapid Micro Biosystems Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

Related News